LLY

Hail Shadow/iStock via Getty Images Bank of America argues that Eli Lilly (NYSE: LLY) and Novo Nordisk (NVO) (OTCPK: NONOF) are “clear leaders” in the market for obesity and diabetes treatments despite encouraging Phase 1 data published by Amgen (NASDAQ: AMGN) recently for his experimental weight loss therapy AMG 133. Novo (NVO) and Lilly (LLY) …

LLY stock, Novo Nordisk will dominate obesity despite Amgen entry (NYSE:LLY) Read More »